Patents by Inventor Stephen A. Udem
Stephen A. Udem has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8647638Abstract: The present invention broadly relates to the synergistic attenuation of vesicular stomatitis virus (VSV), More particularly, the invention relates to the identification of combined mutation classes which synergistically attenuate the pathogenicity of VSV vectors in mammals and immunogenic compositions thereof.Type: GrantFiled: August 31, 2012Date of Patent: February 11, 2014Assignee: Wyeth LLCInventors: David Kirkwood Clarke, Roger Michael Hendry, Stephen A. Udem, Christopher Lee Parks
-
Publication number: 20130023032Abstract: The present invention broadly relates to the synergistic attenuation of vesicular stomatitis virus (VSV), More particularly, the invention relates to the identification of combined mutation classes which synergistically attenuate the pathogenicity of VSV vectors in mammals and immunogenic compositions thereof.Type: ApplicationFiled: August 31, 2012Publication date: January 24, 2013Applicant: Wyeth LLCInventors: David Kirkwood Clarke, Roger Michael Hendry, Stephen A. Udem, Christopher Lee Parks
-
Patent number: 8287878Abstract: The present invention broadly relates to the synergistic attenuation of vesicular stomatitis virus (VSV). More particularly, the invention relates to the identification of combined mutation classes which synergistically attenuate the pathogenicity of VSV vectors in mammals and immunogenic compositions thereof.Type: GrantFiled: April 5, 2005Date of Patent: October 16, 2012Assignee: Wyeth LLCInventors: David Kirkwood Clarke, Roger Michael Hendry, Stephen A. Udem, Christopher Lee Parks
-
Publication number: 20120244113Abstract: A method of inducing an antigen-specific immune response in a mammalian subject includes the steps of administering to the subject an effective amount of a first composition comprising a DNA plasmid comprising a DNA sequence encoding an antigen under the control of regulatory sequences directing expression thereof in a mammalian or vertebrate cell. The method also includes administering to the subject an effective amount of a second composition comprising a recombinant vesicular stomatitis virus (rVSV) comprising a nucleic acid sequence encoding the antigen under the control of regulatory sequences directing expression thereof in the mammalian or vertebrate cell. The rVSV is in one embodiment replication competent. Kits for use in immunizations and therapeutic treatments of disease include the components and instructions for practice of this method.Type: ApplicationFiled: April 24, 2012Publication date: September 27, 2012Applicant: WYETH LLCInventors: John Eldridge, Zimra R. Israel, Michael A. Egan, Stephen A. Udem
-
Publication number: 20090246829Abstract: Isolated nucleic acid molecules comprising a gene segment from a rhesus rotavirus (RRV) or from one of three rhesus:human reassortant viruses are disclosed, including isolated nucleic acid molecules having a sequence selected from the group consisting of: SEQ ID NO: 1-14, inclusive, and isolated nucleic acid molecules encoding a protein having a sequence selected from the group consisting of SEQ ID NO: 15-28, inclusive, as well as variants of the isolated nucleic acid molecules.Type: ApplicationFiled: February 3, 2009Publication date: October 1, 2009Applicants: ServicesInventors: Deborah A. Buonagurio, Alice F. Georgiu, Robert A. Lerch, Bruce B. Mason, Shridhara C. Murthy, Ruth S. Rappaport, Mohinder S. Sidhu, Stephen A. Udem, Timothy J. Zamb
-
Patent number: 7485415Abstract: Isolated nucleic acid molecules comprising a gene segment from a rhesus rotavirus (RRV) or from one of three rhesus: human reassortant viruses are disclosed, including isolated nucleic acid molecules having a sequence selected from the group consisting of: SEQ ID NO: 1-14, inclusive, and isolated nucleic acid molecules encoding a protein having a sequence selected from the group consisting of SEQ ID NO: 15-28, inclusive, as well as variants of the isolated nucleic acid molecules.Type: GrantFiled: February 19, 2003Date of Patent: February 3, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Deborah A. Buonagurio, Alice F. Georgiu, Robert A. Lerch, Bruce B. Mason, Shridhara C. Murthy, Ruth S. Rappaport, Mohinder S. Sidhu, Stephen A. Udem, Timothy J. Zamb
-
Patent number: 7361496Abstract: This invention relates to a method for recombinantly producing, via rescue of mumps virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the mumps virus as an attenuated and/or infectious virus. The recombinant viruses are prepared from cDNA clones, and, accordingly, viruses having defined changes, including nucleotide/polynucleotide deletions, insertions, substitutions and re-arrangements, in the place of the genome are obtained.Type: GrantFiled: August 2, 2000Date of Patent: April 22, 2008Assignee: WyethInventors: David K. Clarke, J. Erik Johnson, Mohinderjit S. Sidhu, Stephen A. Udem
-
Publication number: 20070258997Abstract: This invention relates to a method for recombinantly producing, via rescue of mumps virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the mumps virus as an attenuated and/or infectious virus. The recombinant viruses are prepared from cDNA clones, and, accordingly, viruses having defined changes, including nucleotidelpoly/nucleotide deletions, insertions, substitutions and re-arrangements, in the place of the genome are obtained.Type: ApplicationFiled: June 27, 2007Publication date: November 8, 2007Applicant: WyethInventors: David Clarke, J. Johnson, Mohinderjit Sidhu, Stephen Udem
-
Publication number: 20070253972Abstract: This invention relates to a method for recombinantly producing, via rescue of mumps virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the mumps virus as an attenuated and/or infectious virus. The recombinant viruses are prepared from cDNA clones, and, accordingly, viruses having defined changes, including nucleotide/polynucleotide deletions, insertions, substitutions and re-arrangements, in the place of the genome are obtained.Type: ApplicationFiled: June 27, 2007Publication date: November 1, 2007Applicant: WyethInventors: David Clarke, J. Johnson, Mohinderjit Sidhu, Stephen Udem
-
Publication number: 20070218078Abstract: The present invention broadly relates to the synergistic attenuation of vesicular stomatitis virus (VSV). More particularly, the invention relates to the identification of combined mutation classes which synergistically attenuate the pathogenicity of VSV vectors in mammals and immunogenic compositions thereof.Type: ApplicationFiled: April 5, 2005Publication date: September 20, 2007Applicant: WYETHInventors: David Clarke, Roger Hendry, Stephen Udem, Christopher Parks
-
Publication number: 20070134200Abstract: A method of inducing an antigen-specific immune response in a mammalian subject includes the steps of administering to the subject an effective amount of a first composition comprising a DNA plasmid comprising a DNA sequence encoding an antigen under the control of regulatory sequences directing expression thereof in a mammalian or vertebrate cell. The method also includes administering to the subject an effective amount of a second composition comprising a recombinant vesicular stomatitis virus (rVSV) comprising a nucleic acid sequence encoding the antigen under the control of regulatory sequences directing expression thereof in the mammalian or vertebrate cell. The rVSV is in one embodiment replication competent. Kits for use in immunizations and therapeutic treatments of disease include the components and instructions for practice of this method.Type: ApplicationFiled: March 23, 2004Publication date: June 14, 2007Applicant: WyethInventors: John Eldridge, Zimra Israel, Michael Egan, Stephen Udem
-
Publication number: 20070128222Abstract: Self-propagating, fusogenic blebs are produced from cells infected with a population of Venezuelan Equine Encephalitis virus replicon particles (VRP). The self-propagating, fusogenic nature of the blebs is derived from expression of heterologous genes encoding viral fusion proteins that are incorporated into the replication defective replicon particles. The resulting blebs can be harvested from supernatants of cells displaying severe cytopathic effects. The blebs are used to make immunogenic compositions and devise methods of immunizing mammals against paramyxoviruses such as parainfluenza virus type 3.Type: ApplicationFiled: June 2, 2004Publication date: June 7, 2007Applicant: Wyeth Holdings CorporationInventors: Gerald Kovacs, Xiaoyan Mo, Nikolaos Vasilakis, Sangeeta Bhargava, Timothy Zamb, Stephen Udem
-
Publication number: 20060153870Abstract: Methods for producing infectious, non-segmented, negative-stranded RNA viruses of the Order Mononegavirales are provided that involve coexpression of a viral cDNA along with essential viral proteins, N, P, and L in a host cell transiently transfected with an expression vector encoding an RNA polymerase. In alternate methods, after the host cell is transfected with a viral cDNA expression vector and one or more vectors encoding the RNA polymerase, N protein, P protein, and L protein, the host cell is exposed to an effective heat shock under conditions sufficient to increase recovery of the recombinant virus. In other alternate embodiments, the host cells are transferred after viral rescue begins into co-culture with a plaque expansion cell, typically a monolayer of expansion cells, and the assembled infectious, non-segmented, negative-stranded RNA virus is recovered from the co-culture.Type: ApplicationFiled: November 29, 2005Publication date: July 13, 2006Inventors: Christopher Parks, Stephen Udem, Modinderjit Sidhu
-
Publication number: 20050119471Abstract: Isolated nucleic acid molecules comprising a gene segment from a rhesus rotavirus (RRV) or from one of three rhesus: human reassortant viruses are disclosed, including isolated nucleic acid molecules having a sequence selected from the group consisting of: SEQ ID NO: 1-14, inclusive, and isolated nucleic acid molecules encoding a protein having a sequence selected from the group consisting of SEQ ID NO: 15-28, inclusive, as well as variants of the isolated nucleic acid molecules.Type: ApplicationFiled: February 19, 2003Publication date: June 2, 2005Applicant: THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Deborah Buonagurio, Alice Georgiu, Robert Lerch, Bruce Mason, Shridhara Murthy, Ruth Rappaport, Mohinder Sidhu, Stephen Udem, Timothy Zamb
-
Publication number: 20050089985Abstract: This invention relates to a method for recombinantly producing via rescue canine distemper virus, a nonsegmented, negative-sense, single-stranded RNA virus, and immunogenic compositions formed therefrom. Additional embodiments relate to methods of producing the canine distemper virus as an attenuated and/or infectious viruses. The recombinant viruses can be prepared from cDNA clones, and, accordingly, viruses having defined changes, including nucleotide/polynucleotide deletions, insertions, substitutions and rearrangements, in the genome can be obtained.Type: ApplicationFiled: June 22, 2001Publication date: April 28, 2005Inventors: Christopher Parks, Mohinderjit Sidhu, Pramila Walpita, Gerald Kovacs, Stephen Udem
-
Patent number: 6716431Abstract: The nonstructural protein 4 (NSP4) in the SA11 ATCC rotavirus strain has a histidine at amino acid position 47. This substituted form is more cytotoxic than the NSP4 of the Australia rotavirus strain, which has an asparagine at amino acid position 47. The histidine at amino acid position 47 is mutagenized to another amino acid to produce an alternative form of NSP4 which has reduced toxicity, while retaining its antigenicity and immunogenicity. NSP4 having a glutamic acid at amino acid position 48 is more cytotoxic than NSP4 having a lysine at amino acid position 48. The lysine at amino acid position 48 is mutagenized to another amino acid other than glutamic acid to produce an alternative form of NSP4 which has reduced toxicity, while retaining its antigenicity and immunogenicity.Type: GrantFiled: December 7, 2001Date of Patent: April 6, 2004Assignee: Wyeth Holdings CorporationInventors: Peng Tian, Timothy J. Zamb, Stephen A. Udem
-
Patent number: 6673572Abstract: This invention relates to improved methods for producing nonsegmented, negative-sense, single-stranded RNA viruses of the Order designated Mononegavirales virus, including embodiments relating to methods of producing such viruses as attenuated and/or infectious viruses, such as Measles virus (MV) and respiratory syncytial virus (RSV).Type: GrantFiled: October 1, 2002Date of Patent: January 6, 2004Assignee: Wyeth Holdings CorporationInventors: Christopher L. Parks, Mohinderjit S. Sidhu, Stephen A. Udem, Gerald R. Kovacs
-
Publication number: 20030129729Abstract: This invention relates to improved methods for producing nonsegmented, negative-sense, single-stranded RNA viruses of the Order designated Mononegavirales virus, including embodiments relating to methods of producing such viruses as attenuated and/or infectious viruses, such as Measles virus (MV) and respiratory syncytial virus (RSV).Type: ApplicationFiled: October 1, 2002Publication date: July 10, 2003Applicant: WyethInventors: Christopher L. Parks, Mohinderjit S. Sidhu, Stephen A. Udem, Gerald R. Kovacs